POC products
A novel microfluid-based modular system to address POC challenges within the field of coagulation and hemostasis
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0POC products project word cloud
Explore the words cloud of the POC products project. It provides you a very rough idea of what is the project "POC products" about.
Project "POC products" data sheet
The following table provides information about the project.
| Coordinator |
ILINE MICROSYSTEMS S.L.
Organization address contact info |
| Coordinator Country | Spain [ES] |
| Project website | http://www.ilinemicrosystems.com/nw/ |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3.1.3. (Treating and managing disease) |
| Code Call | H2020-SMEINST-1-2015 |
| Funding Scheme | SME-1 |
| Starting year | 2015 |
| Duration (year-month-day) | from 2015-07-01 to 2015-12-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | ILINE MICROSYSTEMS S.L. | ES (DONOSTIA-SAN SEBASTIAN) | coordinator | 50˙000.00 |
Map
Project objective
The New Oral Anticoagulants (NOACs) are widely advertised, with CAGR 15%/year, as they lack the necessity for monitoring of the patient. It is now corrected by increased levels of renal failure and hemorrhagic events. The project is focused on the validation and industrialization of new IVD POC device that will provide solutions to monitor low molecular weight heparin and NOACs which are not monitored by any existing POC systems. The proposed solution is improving patient care and management and lowering the increasing cost of centralized patient management related to the ageing of the population. This opens a business opportunity for our company since no POC device exists capable of performing similar diagnostic. Our solution has no direct competitors worldwide. The expected outcome is a complete diagnostic system based on proprietary microfluidic Core Technology patented by iLine Microsystems. This will extend the diagnostic range of the POC anticoagulation therapies that now can only be reached by multistep reactions run in centralized labs and accelerate the development of future tests. The feasibility study will focus on the business plan. Market size and niches can be measured for NOACs and their use in patient’s management. Both new lines of product are aiming at distinct market segments, emergencies, hospital tests or independent laboratories. Commercialization will follow the established strategy of sales via worldwide distributors. This approach eliminates the market entry barrier in hospitals and health care. We are building the clinical network including KOLs in the fields of hematology, cardiology and Critical Care where majority of the NOACs are prescribed and monitoring is vital. The proposed solution, due to its modular design and flexibility, has the unique potential for customization and improvements. The modular platform, create the possibility to diversify the markets and design products based on biomarkers outside of hemostasis and coagulation.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "POC PRODUCTS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "POC PRODUCTS" are provided by the European Opendata Portal: CORDIS opendata.